Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions
Department of Quantitative Health Sciences
Adult; Antibodies, Monoclonal; Antirheumatic Agents; Female; Humans; *Information Dissemination; Male; Middle Aged; Risk; Tuberculin Test; Tuberculosis, Pulmonary; Tumor Necrosis Factor-alpha
Bioinformatics | Biostatistics | Epidemiology | Health Services Research
PURPOSE: Following its licensure, tuberculosis (TB) was reported as a potential adverse effect of infliximab. Subsequently, the product circular was changed to recommend tuberculin skin testing before patients received infliximab, which was reinforced by several risk communication efforts. The aim of this study was to evaluate patterns and predictors of documented tuberculin skin testing in patients before and after manufacturer, federal, and academic risk communications.
METHODS: Patients administered infliximab were identified from 11 health plans located throughout the United States, and claims data were examined to determine whether the patients had received a tuberculin skin test. Patients were divided into three cohorts depending on the timing of their first infliximab treatment in relation to the risk communication efforts.
RESULTS: The overall tuberculin skin testing rate doubled from 15.4% in the first cohort to 30.9% in the last cohort, while the rate of pre-infliximab treatment testing increased from 0 to 27.7% (Chi-squared test for trend, p < 0.0001 for both). Tuberculin skin testing rates were significantly higher in women, those with a diagnosis of rheumatoid or psoriatic arthritis, and those with a rheumatologist as prescriber. After multivariable analysis, only rheumatologist remained significantly associated with tuberculin skin testing.
CONCLUSIONS: Although the tuberculin skin testing rate was relatively low overall, tuberculin skin testing doubled over 30 months of ongoing risk communication efforts and under ascertainment likely occurred. We also found variation in the tuberculin skin testing rate associated with physician specialty. This study demonstrates a significant change in patient care following risk communication efforts.
Rights and Permissions
Citation: Pharmacoepidemiol Drug Saf. 2006 Jan;15(1):11-8. Link to article on publisher's site
Pharmacoepidemiology and drug safety
Shatin, Deborah; Rawson, Nigel S.; Curtis, Jeffrey R.; Braun, M. Miles; Martin, Carolyn K.; Moreland, Larry W.; Becker, Angela F.; Patkar, Nivedita M.; Allison, Jeroan J.; and Saag, Kenneth G., "Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions" (2005). Quantitative Health Sciences Publications and Presentations. 798.